Implementation of an In-House Platform for Rapid Screening of SARS-CoV-2 Genome Variations.

COVID-19 Nested RT-PCR SARS-CoV-2 variants Sanger sequencing Spike gene

Journal

Archives of Iranian medicine
ISSN: 1735-3947
Titre abrégé: Arch Iran Med
Pays: Iran
ID NLM: 100889644

Informations de publication

Date de publication:
01 02 2023
Historique:
received: 12 07 2022
accepted: 16 11 2022
medline: 8 8 2023
pubmed: 6 8 2023
entrez: 6 8 2023
Statut: epublish

Résumé

Global real-time monitoring of SARS-CoV-2 variants is crucial to controlling the COVID-19 outbreak. The purpose of this study was to set up a Sanger-based platform for massive SARS-CoV-2 variant tracking in laboratories in low-resource settings. We used nested RT-PCR assay, Sanger sequencing and lineage assignment for 930-bp of the SARS-CoV-2 spike gene, which harbors specific variants of concern (VOCs) mutations. We set up our platform by comparing its results with whole genome sequencing (WGS) data on 137 SARS-CoV-2 positive samples. Then, we applied it on 1028 samples from March-September 2021. In total, 125 out of 137 samples showed 91.24% concordance in mutation detection. In lineage assignment, 123 out of 137 samples demonstrated 89.78% concordance, 65 of which were assigned as VOCs and showed 100% concordance. Of 1028 samples screened by our in-house method, 78 distinct mutations were detected. The most common mutations were: S:D614G (21.91%), S:P681R (12.19%), S:L452R (12.15%), S:T478K (12.15%), S:N501Y (8.91%), S:A570D (8.89%), S:P681H (8.89%), S:T716I (8.74%), S:L699I (3.50%) and S:S477N (0.28%). Of 1028 samples, 980 were attributed as VOCs, which include the Delta (B.1.617.2) and Alpha (B.1.1.7) variants. Our proposed in-house Sanger-based assay for SARS-CoV-2 lineage assignment is an accessible strategy in countries with poor infrastructure facilities. It can be applied in the rapid tracking of SARS-CoV-2 VOCs in the SARS-CoV-2 pandemic.

Sections du résumé

BACKGROUND
Global real-time monitoring of SARS-CoV-2 variants is crucial to controlling the COVID-19 outbreak. The purpose of this study was to set up a Sanger-based platform for massive SARS-CoV-2 variant tracking in laboratories in low-resource settings.
METHODS
We used nested RT-PCR assay, Sanger sequencing and lineage assignment for 930-bp of the SARS-CoV-2 spike gene, which harbors specific variants of concern (VOCs) mutations. We set up our platform by comparing its results with whole genome sequencing (WGS) data on 137 SARS-CoV-2 positive samples. Then, we applied it on 1028 samples from March-September 2021.
RESULTS
In total, 125 out of 137 samples showed 91.24% concordance in mutation detection. In lineage assignment, 123 out of 137 samples demonstrated 89.78% concordance, 65 of which were assigned as VOCs and showed 100% concordance. Of 1028 samples screened by our in-house method, 78 distinct mutations were detected. The most common mutations were: S:D614G (21.91%), S:P681R (12.19%), S:L452R (12.15%), S:T478K (12.15%), S:N501Y (8.91%), S:A570D (8.89%), S:P681H (8.89%), S:T716I (8.74%), S:L699I (3.50%) and S:S477N (0.28%). Of 1028 samples, 980 were attributed as VOCs, which include the Delta (B.1.617.2) and Alpha (B.1.1.7) variants.
CONCLUSION
Our proposed in-house Sanger-based assay for SARS-CoV-2 lineage assignment is an accessible strategy in countries with poor infrastructure facilities. It can be applied in the rapid tracking of SARS-CoV-2 VOCs in the SARS-CoV-2 pandemic.

Identifiants

pubmed: 37543926
doi: 10.34172/aim.2023.12
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-75

Informations de copyright

© 2023 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Auteurs

Farzane Zare Ashrafi (F)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Marzieh Mohseni (M)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.

Maryam Beheshtian (M)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.

Zohreh Fattahi (Z)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.

Fatemeh Ghodratpour (F)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Fatemeh Keshavarzi (F)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Hanieh Behravan (H)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Marzieh Kalhor (M)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Khadijeh Jalalvand (K)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Maryam Azad (M)

Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.

Mahdieh Koshki (M)

Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.

Ali Jafarpour (A)

Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.
Gerash Amir-al-Momenin Medical and Educational Center, Gerash University of Medical Sciences, Gerash, Iran.

Azam Ghaziasadi (A)

Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.

Alireza Abdollahi (A)

Department of Pathology, School of Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Iran.

Seyed Jalal Kiani (SJ)

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Angila Ataei-Pirkooh (A)

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Iman Rezaei Azhar (I)

Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.

Farah Bokharaei-Salim (F)

Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Mohammad Reza Haghshenas (MR)

Department of Medical Microbiology, Antimicrobial Resistance Research Center, Communicable Diseases Institute, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Farhang Babamahmoodi (F)

Department of Medical Microbiology, Antimicrobial Resistance Research Center, Communicable Diseases Institute, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Zakiye Mokhames (Z)

Department of Molecular Diagnostic, Emam Ali Educational and Therapeutic Center, Alborz University of Medical Sciences, Karaj, Iran.

Alireza Soleimani (A)

Department of Infectious Diseases, Imam Ali hospital, Alborz University of Medical Sciences, Karaj, Iran.

Masood Ziaee (M)

Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Davod Javanmard (D)

Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Shokouh Ghafari (S)

Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Akram Ezani (A)

Qazvin Deputy of Treatment Reference Laboratory, Qazvin University of Medical Sciences, Qazvin, Iran.

Alireza Ansari Moghaddam (A)

Health Promotion Research Center, Zahedan University of Medical Science, Zahedan, Iran.

Fariba Shahraki-Sanavi (F)

Health Promotion Research Center, Zahedan University of Medical Science, Zahedan, Iran.

Seyed Mohammad Hashemi Shahri (SM)

Infection Disease and Tropical Medicine Research Center, Zahedan University of Medical Science, Zahedan, Iran.

Azarakhsh Azaran (A)

Department of Medical Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Farid Yousefi (F)

Department of Infectious Diseases, School of Medicine, Razi Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Afagh Moattari (A)

Department of Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Mohsen Moghadami (M)

Health policy research center, Shiraz University of medical sciences, Shiraz, Iran.

Hamed Fakhim (H)

Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Behrooz Ataei (B)

Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Elahe Nasri (E)

Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Vahdat Poortahmasebi (V)

Department of Bacteriology and Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Mojtaba Varshochi (M)

Infectious and Tropical Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.

Ali Mojtahedi (A)

Microbiology Department, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.

Farid Jalilian (F)

Department of Medical Virology, Faculty of Medicine, Hamadan University of Medical sciences, Hamadan, Iran.

Mohammad Khazeni (M)

Booali lab, Molecular & Virology Diagnostic Section, Qom, Iran.

Abdolvahab Moradi (A)

Golestan University of Medical Sciences, Gorgan, Iran.

Alijan Tabarraei (A)

Golestan University of Medical Sciences, Gorgan, Iran.

Ahmad Piroozmand (A)

Department of Microbiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.

Yousef Yahyapour (Y)

Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran.

Masoumeh Bayani (M)

Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran.

Amir Aboofazeli (A)

Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.

Parsa Ghafari (P)

Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.

Fariba Keramat (F)

Brucellosis Research Center, Hamedan University of Medical Science, Hamadan, Iran.

Mahsa Tavakoli (M)

COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.

Tahmineh Jalali (T)

COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.
Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran.

Mohammad Hassan Pouriayevali (MH)

COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.
Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran.

Mostafa Salehi-Vaziri (M)

COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.
Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran.

Hamid Reza Khorram Khorshid (HR)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Reza Najafipour (R)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Cell and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.

Reza Malekzadeh (R)

Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Kimia Kahrizi (K)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Seyed Mohammad Jazayeri (SM)

Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.

Hossein Najmabadi (H)

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH